|
Delayed
TEL AVIV STOCK EXCHANGE
06:38:16 2026-11-03 am EST
|
5-day change | 1st Jan Change | ||
| 2,254.00 ILa | -2.00% |
|
-7.87% | -0.09% |
| Oct. 06 | Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel | MT |
| Oct. 06 | Kamada Ltd. Announces Expansion of Biosimilars Portfolio with Launch of Two Additional Products in Israel | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 423M | - | - | - | ||
| 1,257B | |||||
| 651B | |||||
| 510B | |||||
| 388B | |||||
| 366B |
- Stock Market
- Stocks
- KMDA Stock
- Charts Kamada Ltd.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
